Who Says FDA Can't Have Your Marketing Plan?
This article was originally published in RPM Report
Executive Summary
Industry fought hard to prohibit FDA from having the authority to review marketing plans as part of FDAAA. The REMS for Xenazine suggests that the legislative success may have been a Pyrrhic victory; FDA is going ahead and grabbing authority over the marketing plans and procedures for some drugs.
You may also be interested in...
Waking Up to REMS (Part 3): Redefining Marketing
FDA's new post-marketing safety authorities place unprecedented burdens on pharmaceutical marketers. But they do something else: redefine a favorite target of industry critics as a regulatory requirement rather than a suspicious activity.
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
The Impact of FDAAA On Drug Approvals: Setting the Baseline
An analysis of the first six months of the new era in drug regulation shows that FDA is enthusiastically and creatively applying its new drug safety tools. Biopharma companies will be watching carefully to see how the metrics of the FDAAA era move over time.